Related references
Note: Only part of the references are listed.A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
J. Portnow et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
Christina D. Befani et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents
Monika Szeliga et al.
JOURNAL OF NEUROCHEMISTRY (2012)
STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
Shinji Kohsaka et al.
MOLECULAR CANCER THERAPEUTICS (2012)
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
Wei Zhang et al.
NEURO-ONCOLOGY (2012)
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice
Michael Weller et al.
NEURO-ONCOLOGY (2012)
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression
L. Persano et al.
CELL DEATH & DISEASE (2012)
Current Concepts and Management of Glioblastoma
Matthias Preusser et al.
ANNALS OF NEUROLOGY (2011)
p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: A mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis
Dai-Wu Seol
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction
Marta Brell et al.
BMC CANCER (2011)
Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells
Anna Patrikidou et al.
CANCER CELL INTERNATIONAL (2011)
Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis
Thomas Unterkircher et al.
CLINICAL CANCER RESEARCH (2011)
Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: Correlation with IL-6, VEGF and microvessel morphometry
Christina Piperi et al.
CYTOKINE (2011)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
Joerg Felsberg et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image
Ryota Mashiko et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
Simone Kreth et al.
PLOS ONE (2011)
MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis
Atsushi Sato et al.
STEM CELLS (2011)
Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome
Angelica A. Saetta et al.
VIRCHOWS ARCHIV (2011)
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
K. A. van Nifterik et al.
BRITISH JOURNAL OF CANCER (2010)
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma
Markus Christmann et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma
Yukihiko Sonoda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib
Ioannis A. Voutsadakis et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2010)
Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation
Zheng Tianhu et al.
MOLECULAR BIOLOGY REPORTS (2010)
O-6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Alba A. Brandes et al.
NEURO-ONCOLOGY (2010)
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
K-F Chen et al.
ONCOGENE (2010)
PHASE I TRIAL USING PROTEASOME INHIBITOR BORTEZOMIB AND CONCURRENT TEMOZOLOMIDE AND RADIOTHERAPY FOR CENTRAL NERVOUS SYSTEM MALIGNANCIES
Gregory J. Kubicek et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NFκB activity Implications for cancer therapy
Anwesha Dey et al.
CELL CYCLE (2008)
Expression of nuclear factor-κB in human astrocytomas:: relation to pIκBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival
Penelope Korkolopoulou et al.
HUMAN PATHOLOGY (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach
David Capper et al.
ACTA NEUROPATHOLOGICA (2008)
Novel mechanism whereby nuclear factor κB mediates DNA damage repair through regulation of O6-methylguanine-DNA-methyltransferase
Iris Lavon et al.
CANCER RESEARCH (2007)
Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme
Tamar Fisher et al.
CANCER JOURNAL (2007)
Inhibition of nuclear factor-κB activity by temozolomide involves O6-methylguanine-induced inhibition of p65 DNA binding
Bakhtiar Yamini et al.
CANCER RESEARCH (2007)
Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1α
Ilias Mylonis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bortezomib in the treatment of cancer
Aldo M. Roccaro et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2006)
Akt1 activation can augment hypoxia-inducible factor-1α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway
Nabendu Pore et al.
MOLECULAR CANCER RESEARCH (2006)
Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas
M Bredel et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
JL Fischel et al.
BRITISH JOURNAL OF CANCER (2005)
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)
D Yin et al.
ONCOGENE (2005)
Hypoxia-inducible factor 1α/vascular endothelial growth factor axis in astrocytomas.: Associations with microvessel morphometry, proliferation and prognosis
P Korkolopoulou et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2004)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
T Hideshima et al.
ONCOGENE (2003)
The proteasome: structure, function, and role in the cell
J Adams
CANCER TREATMENT REVIEWS (2003)
Oxygen-dependent and -independent regulation of HIF-1alpha
YS Chun et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2002)
Degradation of the alkylated form of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase
M Xu-Welliver et al.
CARCINOGENESIS (2002)
Regulation of the human O6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300
KK Bhakat et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
